Contineum Therapeutics (CTNM) Non Operating Income (2023 - 2026)

Contineum Therapeutics' Non Operating Income history runs 4 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 15.47% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $8.7 million, a 6.11% decrease from a year earlier, with the FY2025 full-year figure at $8.1 million, down 6.43% from the prior year.
• Non Operating Income improved to $2.4 million in Q1 2026 per CTNM's latest filing, from $2.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.4 million in Q2 2023 and bottomed at $291000.0 in Q1 2023.
• The 4-year median for Non Operating Income is $2.0 million (2025), against an average of $2.0 million.
• Biggest YoY gain for Non Operating Income was 419.93% in 2024; the steepest drop was 42.34% in 2024.
• Year by year, Non Operating Income stood at $1.7 million in 2023, then soared by 42.15% to $2.5 million in 2024, then fell by 21.07% to $2.0 million in 2025, then climbed by 24.96% to $2.4 million in 2026.
• Per Business Quant, the three latest CTNM Non Operating Income figures stand at $2.4 million (Q1 2026), $2.0 million (Q4 2025), and $2.4 million (Q3 2025).